Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.59 |
| ▸ | HNF4A | P41235 | 3/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032656 | 0.93 | RXRA (0.61) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6033022 | 0.92 | RARA (0.52) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6033001 | 0.91 | RXRA (0.50) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6033265 | 0.89 | RXRA (0.52) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6033276 | 0.89 | RXRA (0.51) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6559941 | 0.89 | RXRA (0.48) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6033101 | 0.87 | RXRA (0.47) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6560072 | 0.87 | RXRA (0.50) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6560730 | 0.86 | RXRA (0.48) | RXRAPPARGNR1H3HNF4ARXRB | |
| SCHEMBL6032956 | 0.84 | RXRA (0.46) | RXRAPPARGHNF4ARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | claimed |
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | RXRA 1865/4885PPARG 313/4885NR1H3 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.